ClinicalTrials.gg
TerminatedNCT00057382Updated Jun 24, 2005

T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients

A Phase 2/3 interventional study of T138067 intravenous and doxorubicin intravenous in Hepatocellular Carcinoma, sponsored by Tularik. Terminated at 76 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Tularik (part of Amgen) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
750
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing doxorubicin in Carcinoma, Hepatocellular — none open to participants now, 2 under way, 1 of them phase 3. Doxorubicin · Carcinoma, Hepatocellular.

Enrollment
Largest of 24
750 · median 44
Started
2003
the only one that year
Phase 2/3
2 of 26
none open now
Registered
7th of 26
by date

Among the 26 studies testing doxorubicin in Carcinoma, Hepatocellular, this one has the largest enrollment of the 24 interventional ones that give a count, is the only one that started in 2003, is one of 2 in phase 2/3, and was the 7th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

None of the 26 studies testing doxorubicin in Carcinoma, Hepatocellular is open now. The open studies under Carcinoma, Hepatocellular, anywhere →

About doxorubicin

Doxorubicin: first FDA approval 1974 (DOXORUBICIN HYDROCHLORIDE), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing doxorubicin in Carcinoma, Hepatocellular as a file.
02

Study summary

This is an international, multicenter, randomized study of intravenous T138067 versus intravenous doxorubicin in hepatocellular carcinoma (liver cancer). Patients can not have been treated before with chemotherapy and surgery is not recommended for their cancer. A total of 750 subjects will be enrolled in this study.

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • liver cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria include:

  • pathologic diagnosis of unresectable HCC
  • chemotherapy-naïve for HCC
  • Class A or B liver disease
  • (i.e., at least one lesion that is at least 20 mm in one dimension) on computerized tomography (CT) scan or magnetic resonance imaging (MRI) or at least one lesion that is at least 10 mm on spiral CT scan
  • Performance Status of ≥ 70%
  • of ≥ 12 weeks
  • adequate hematologic function (i.e., [ANC] of ≥ 1500 cells/mm3, count of ≥ 80,000 cells/mm3, of ≥ 8.5 g/dL)
  • total of ≤ 1.5 (ULN)
  • (AST) and alanine transaminase (ALT) ≤ 5 ULN
  • serum creatinine of ≤ 2 x ULN

Key exclusion criteria include:

  • severe, concurrent disease that would make the subject inappropriate for enrollment
  • Subjects who have received prior intravenous or intra-arterial chemotherapy, chemoembolization, intratumoral ethanol injection, cryosurgery, radiofrequency ablation, or embolization for their HCC. (note: prior surgical resection, immunotherapy, hormonal therapy, radiotherapy, and/or orthotopic liver transplantation are allowed)
  • history of other cancer within the past 5 years other than adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix
  • (NYHA) class III or IV heart disease or a of \<50% or acute anginal symptoms
  • females who are pregnant or breast-feeding
  • received any agent within 4 weeks of enrollment
  • history of central nervous system or carcinomatous meningitis
  • clinically apparent ascites
  • major surgery within 4 weeks of study enrollment
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
750 participants
06

Study locations

76 sites
  • University of Alabama
    Birmingham, Alabama 35294, United States
  • University of California at San Francisco
    San Francisco, California 94115, United States
  • VA Medical Center
    Miami, Florida 33125, United States
  • University of Miami
    Miami, Florida 33136, United States
  • H. Lee Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Loyola University of Chicago
    Maywood, Illinois 60153, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • UT Southwestern Medical Center - Dallas
    Dallas, Texas 75390-9125, United States
  • Hospital Vera Cruz
    Belo Horizonte, 30190130, Brazil
  • Hospital Mater Dei - Departamento de Oncologia
    Belo Horizonte, 30190131, Brazil
  • Irmandade Santa Casa de Misericórdia de Porto Alegre - Unidade de Apoio à Pesquisa
    Porto Alegre, 90020090, Brazil
  • Hospital das Clínicas da Faculdade de Medicina da USP
    São Paulo, 5403000, Brazil
  • Cancer Center, Sun Yat-Sen Unversity
    Guangzhou, Guangdong 510060, China
  • Guangzhou Nanfang Hospital
    Guangzhou, Guangdong 510515, China
  • Queen Mary Hospital
    Hong Kong, Hong Kong, China
  • Nanjing Ba Yi Hospital of PLA
    Nanjing, Jiangsu 210002, China
  • 1st Affiliated Hospital of Xi An Jiao Tong University
    Xi AN, Shanxi 710061, China
  • Taipei Veteran General Hospital
    Taipei, Taiwan, China
  • Chang Gung Memorial Hospital
    Tao-Yuan, Taiwan, China
  • Cancer Hospital of Chinese Academy of Medical Science (CAMS)
    Beijing, 100021, China
  • Beijing Cancer Hospital of Peking University
    Beijing, 100036, China
  • Gereral Hospital of PLA
    Beijing, 100853, China
  • Chongqing Southwest Hospital
    Chongqing, 400038, China
  • Prince Wales Hosptial
    Hong Kong, China
  • The Affiliated Hospital of Medical College Qingdao University
    Qingdao, 266003, China
  • Liver Cancer Institute, Zhongshan Hospital, Fudan University
    Shanghai, 200032, China
  • Shanghai Changzheng Hospital
    Shanghai, 200070, China
  • Katedra i Klinika Onkologii i Radioterapi Akademii Medycznej
    GdaDsk, 80-211, Poland
  • Oddział Chemioterapii
    Olsztyn, 10-228, Poland
  • Klinika Katedry Onkologii AM
    Poznan, 61-878, Poland
  • San Juan Medical Center
    San Juan, 00927, Puerto Rico
  • Arkhangelsk Redional Oncology Center, Department of Chemotherapy
    Arkhangelsk, 143045, Russian Federation
  • Barnaul, 656049, Russian Federation
  • Cheliabinsk Regional Oncology Center
    Chelyabinsk, 545087, Russian Federation
  • Irkutsk Regional Oncology Center
    Irkutsk, 664035, Russian Federation
  • Kazan State Medical University
    Kazan, 420012, Russian Federation
  • Kazan Republican Oncology Clinical Center
    Kazan, 420029, Russian Federation
  • Krasnodar City Oncology Center
    Krasnodar, 350040, Russian Federation
  • Krasnoyarsk Regional Oncology Center
    Krasnoyarsk, 660133, Russian Federation
  • Lipetsk
    Lipetsk, 398005, Russian Federation
  • Blokhin Cancer Research Center
    Moscow, 115478, Russian Federation
  • Central Clinical Hospital of the President of the Russian Federation
    Moscow, 121356, Russian Federation
  • Central Clinical Hospital of the Ministry of Transport
    Moscow, 129128, Russian Federation
  • Novosibirks Municipal Clinical Hospital #1
    Novosibirsk, 630047, Russian Federation
  • Russian Academy of Medical Sciences
    Obninsk, 249020, Russian Federation
  • Omsk Regional Oncology Center
    Omsk 13, Russian Federation
  • Orenburg Regional Oncology Center
    Orenburg, 460021, Russian Federation
  • Moscow Oncology Hospital #62
    P/O Stepanovskoye, 143423, Russian Federation
  • Rostov Research Oncology Institute
    Rostov-on-Don, 344713, Russian Federation
  • Central Research Institute of Radiology of the Ministry of Health of Russian Federation
    St Petersburg, 189646, Russian Federation
  • Medical Academy of Postgraduate Education, St. Petersburg
    St Petersburg, 193015, Russian Federation
  • St. Petersburg Mechnikov State Medical Academy
    St Petersburg, 195065, Russian Federation
  • St. Petersburg Oncology Center
    St Petersburg, 197022, Russian Federation
  • Stavropol Regional Oncology Center
    Stavropol, 355018, Russian Federation
  • Tomsk Regional Research Institute of Oncology
    Tomsk, 634028, Russian Federation
  • Bashkiria Republican Oncology Center
    Ufa, 450054, Russian Federation
  • Voronezh Regional Clinical Oncology Center
    Voronezh, 394000, Russian Federation
  • Yaroslavl Regional Oncology Center
    Yaroslavl, 150054, Russian Federation
  • Zhitomir Regional Hospital
    Zhitomir, 10002, Russian Federation
  • National University Hospital
    Singapore, 119074, Singapore
  • Eastern Cape Oncology Centre
    Port Elizabeth, South Africa
  • Khon Kaen University
    Khon Kaen, 40002, Thailand
  • Chiangmai University
    Muang Chiangmai, 50200, Thailand
  • Dnepropetrovsk State Medical Academy
    Dnepropetrovsk, 49102, Ukraine
  • Donetsk Regional Antitumor Center
    Donetsk, 83092, Ukraine
  • Kiev Central Military Clinical Hospital
    Kiev, 01133, Ukraine
  • Kiev Oncology Institute of Ukrainian Academy of Medical Science
    Kiev, 03022, Ukraine
  • Krivorojsky City Oncology Center
    Krivoy Rog, 50048, Ukraine
  • Lvov State Medical University
    Lvov, 79031, Ukraine
  • Poltava Regional Clinical Oncological Center
    Poltava, 36011, Ukraine
  • Vinnitsa Regional Clinical Oncological Center
    Vinnitsa, 21021, Ukraine
  • Zaporozhje State Medical Institute of Postgraduate Education
    Zaporozhye, 69104, Ukraine
  • Addenbrookes Hospital
    Cambridge, CB2 2QQ, United Kingdom
  • Royal Free Hospital
    London, NW3 2QG, United Kingdom
  • Hammersmith Hospital
    London, W12 OH5, United Kingdom
  • Christie Hospital
    Manchester, M20 4BX, United Kingdom
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00057382
Lead sponsor
Tularik
First posted
Apr 2, 2003
Start date
Mar 2003
Last update
Jun 24, 2005

Study contacts

Mohammad Hirmand, MD
study director · Tularik
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2004. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Batabulin · Doxorubicin

Start the discussion